top of page
Science Lab

Drug Discovery

Leveraging molecular interactions to develop therapeutic compounds

Challenge

Drug discovery faces many challenges, encompassing target identification, compound screening, and optimization of drug candidates for efficacy and safety. Accurate characterization of molecular interactions within complex biological systems is essential for understanding disease mechanisms and identifying potential therapeutic targets. Additionally, navigating the vast chemical space to find lead compounds with desirable pharmacological properties presents a significant hurdle.

Solutions

Our SPR devices provide invaluable insights into molecular interactions, offering researchers a precise understanding of candidate compounds' binding kinetics and affinity. Our technology facilitates efficient screening and selection processes, enabling the identification of promising leads early in the drug discovery journey. With Affinite Instruments' SPR devices, researchers can navigate drug discovery challenges with confidence, accelerating the development of innovative therapeutics

PRO Profile.png
Affipump Profile.png

P4PRO and Affipump

Compatible Targets

icon7.png
icon5.png
icon4.png
icon2.png
icon6.png
icon3.png

Real-World Applications

Identifying biological targets

The identification of biological targets is a crucial phase in drug discovery where researchers aim to pinpoint specific molecules, such as proteins or nucleic acids, that play key roles in disease processes. By elucidating binding affinities and specificity, studies between biomolecules and small molecules provide invaluable insights into potential drug targets. Leveraging SPR and innovative approaches, researchers can unravel complex biological interactions, paving the way for the development of novel therapeutic interventions across various diseases and conditions.

image.png

Efficient lead screening

image.png

SPR's label-free nature minimizes the need for extensive sample preparation, making it an ideal technique for small-scale lead screening efforts in drug discovery endeavors. By immobilizing target proteins, researchers can screen small compound leads to identify potential drug candidates based on their binding affinity and kinetics. This label-free technique allows for rapid evaluation of multiple compounds, aiding in the efficient selection of promising leads for further optimization.

Bioanalytical DNA Detection

Cytokine release syndrome is a form of systemic inflammatory response syndrome that arises as a complication of some diseases or infections, and is also an adverse effect of some monoclonal antibody drugs and other treatments. Severe cases have been called “cytokine storms” and can be fatal. Understanding the mechanism of inflammation is important. Here, the P4SPR was deployed to investigate the binding of a gene (EBI3) to IL-6, a pro-inflammatory cytokine. This unexpected observation could lead to a new therapeutic biologic for autoimmune diseases. 

Bioanalytical DNA detection
Bioanalytical Small peptide detection

CD36 Small Molecule Detection

CD36 is a scavenger receptor important in age-related macular degeneration and other diseases. CD36 transmembrane proteins have diverse roles in lipid uptake, cell adhesion and pathogen sensing. Despite numerous in vitro studies, how they act in native cellular contexts is poorly understood. In an investigation with a Drosophila CD36 homologue, SNMP1, the P4SPR was employed to assess small-molecule interactions with a CD36 sensor chip.

Application Notes

App note 3.png

Application note #3

Transmembrane protein CD36 detection of small molecules

App note 7 web.png

Application note #7

Determination of KD for drug discovery

bottom of page